APRETUDE Drug Patent Profile

Which patents cover Apretude, and when can generic versions of Apretude launch?

Apretude is a drug marketed by Viiv Hlthcare and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in APRETUDE is cabotegravir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cabotegravir profile page.

DrugPatentWatch^® Generic Entry Outlook for Apretude

Apretude was eligible for patent challenges on January 21, 2025.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for APRETUDE

US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	53
Clinical Trials:	5
Patent Applications:	831
Drug Prices:	Drug price information for APRETUDE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for APRETUDE
What excipients (inactive ingredients) are in APRETUDE?	APRETUDE excipients list
DailyMed Link:	APRETUDE at DailyMed

See drug prices for APRETUDE

Recent Clinical Trials for APRETUDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
PPD	Phase 3
GlaxoSmithKline	Phase 3
ViiV Healthcare	Phase 3

See all APRETUDE clinical trials

US Patents and Regulatory Information for APRETUDE

APRETUDE is protected by four US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499-001	Dec 20, 2021		RX	Yes	Yes	12,138,264		Y
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499-001	Dec 20, 2021		RX	Yes	Yes	11,224,597		Y
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499-001	Dec 20, 2021		RX	Yes	Yes	10,927,129		Y	Y
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499-001	Dec 20, 2021		RX	Yes	Yes	8,410,103		Y	Y
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499-001	Dec 20, 2021		RX	Yes	Yes

Expired US Patents for APRETUDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	APRETUDE	cabotegravir	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	215499-001	Dec 20, 2021	10,927,129

EU/EMA Drug Approvals for APRETUDE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
ViiV Healthcare B.V.	Vocabria	cabotegravir	EMEA/H/C/004976Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA	Authorised	no	no	no	2020-12-17
ViiV Healthcare B.V.	Apretude	cabotegravir	EMEA/H/C/005756Apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4.2, 4.4 and 5.1).	Authorised	no	no	no	2023-09-15

International Patents for APRETUDE

When does loss-of-exclusivity occur for APRETUDE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Lithuania

Mexico

Montenegro

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering APRETUDE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E516026
Australia	2006239177	Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Australia	2006307101	Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
Brazil	PI0610030	composto, processo para a preparação de um composto, método de tratamento de uma infecção por hiv em um humano, uso de um composto, e, composição farmacêutica
Brazil	PI0617842	composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica

Supplementary Protection Certificates for APRETUDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1874117	C300676	Netherlands		PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, MET INBEGRIP VAN DOLUTEGRAVIR NATRIUM; REGISTRATION NO/DATE: EU/1/13/892 20140121
1874117	CA 2014 00032	Denmark		PRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140116
1874117	PA2014021	Lithuania		PRODUCT NAME: DOLUTEGRAVIRUM NATRICUM; REGISTRATION NO/DATE: EU/1/13/892/001, 2014 01 16 EU/1/13/892/002 20140116
1874117	1490036-9	Sweden		PRODUCT NAME: DOLUTEGRAVIR ELLER ETT FARMACEUTISKT ACCEPTABELT SALT ELLER SOLVAT DAERAV, INKLUSIVE DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892 20140116
1874117	C20140020 00130	Estonia		PRODUCT NAME: DOLUTEGRAVIIR;REG NO/DATE: K(2014)305 (LOPLIK) 21.01.2014

Apretude Market Dynamics, Financial Trajectory, Patents, and Generic Entry Risk

Last updated: August 22, 2026

Apretude, ViiV Healthcare’s long-acting injectable cabotegravir for HIV pre-exposure prophylaxis, has created a differentiated PrEP category but remains commercially constrained by injection logistics, reimbursement, provider capacity, and competition from low-cost oral generics. Its strategic value is greater than its current sales contribution because it extends ViiV’s cabotegravir franchise beyond treatment into prevention.

Apretude received FDA approval in December 2021. The product is administered as two initiation injections one month apart, followed by an injection every two months. Clinical efficacy exceeded daily oral Truvada in the HPTN 083 and HPTN 084 trials, although the product requires healthcare-system participation and strict appointment adherence.[1][2][3]

What is Apretude and how does it compete in HIV prevention?

Apretude is an extended-release nanosuspension of cabotegravir, an integrase strand transfer inhibitor. It is approved for HIV-negative adults and adolescents weighing at least 35 kilograms who are at risk of sexually acquired HIV infection.

The product competes across three main dimensions:

Product	Active ingredients	Administration	Commercial position
Apretude	Cabotegravir	Injection every two months after initiation	Long-acting prevention
Truvada and authorized generics	Emtricitabine/tenofovir disoproxil fumarate	Daily oral tablet	Lowest-cost oral PrEP
Descovy	Emtricitabine/tenofovir alafenamide	Daily oral tablet	Oral PrEP for approved populations, excluding receptive vaginal sex under the original FDA indication
Generic emtricitabine/tenofovir DF	Emtricitabine/tenofovir disoproxil fumarate	Daily oral tablet	Price-led alternative

Apretude’s clinical advantage is reduced dosing frequency. Its commercial disadvantage is that patients must return to a clinic for administration. Oral PrEP can be prescribed through retail, mail-order, telehealth, and primary-care channels.

The product’s target population is also broader than its initial commercial penetration. Apretude can appeal to patients with adherence challenges, pill fatigue, privacy concerns, stigma associated with daily tablets, or unstable access to oral medication.

What is the financial trajectory for Apretude?

Apretude has moved from launch-stage sales to a growing but still relatively small contributor to ViiV Healthcare’s HIV portfolio. ViiV and parent company GSK have reported strong uptake, but public financial reporting provides less product-level detail than it provides for flagship treatment products such as Dovato, Triumeq, and Cabenuva.

GSK reported total ViiV sales of approximately £7.9 billion in 2023, compared with approximately £7.4 billion in 2022. Growth was driven primarily by newer HIV treatment products, especially Dovato and Cabenuva, rather than Apretude alone.[4]

Apretude commercial indicators

Indicator	Assessment
Launch	FDA approval in December 2021
Initial commercial market	United States, followed by selected international markets
Revenue profile	Early-growth product within ViiV’s HIV portfolio
Main payer issue	High acquisition and administration cost compared with generic oral PrEP
Main growth driver	Expansion of long-acting prevention and increased HIV testing and prevention access
Main constraint	Clinic visits, injection capacity, reimbursement complexity, and adherence to dosing appointments
Strategic role	Prevention platform for cabotegravir and a hedge against treatment-market concentration

Apretude’s financial trajectory should be evaluated through three stages.

2022: launch and access formation

The first commercial year was dominated by formulary placement, provider education, distribution setup, patient-support programs, and payer negotiations. Sales were limited by the need to establish injection infrastructure and by the time required for clinicians to adopt a new prevention protocol.

The product also entered a market where generic oral PrEP was already widely available. That made the reimbursement case dependent on outcomes beyond drug price, including persistence, adherence, and prevention of HIV infections among patients who do not reliably take daily tablets.

2023 to 2024: demand expansion with operational friction

Apretude gained visibility as long-acting HIV prevention became a larger public-health priority. Adoption increased through infectious-disease clinics, sexual-health programs, and public-sector channels.

The primary commercial friction remained execution rather than clinical differentiation. Patients must complete HIV testing before each injection, maintain a two-month dosing schedule, and manage the risk of a prolonged pharmacokinetic “tail” if treatment is discontinued without oral coverage. The tail can expose patients to subtherapeutic cabotegravir concentrations and potential integrase resistance.

Longer term: potential category expansion

Apretude’s upside depends on whether long-acting PrEP becomes a routine option in primary care and public-health systems. A wider provider base could increase volume substantially. Conversely, if use remains concentrated in specialist clinics, sales growth may be slower than the clinical efficacy data suggest.

ViiV also has a strategic incentive to use Apretude as part of a broader long-acting HIV franchise that includes Cabenuva, the cabotegravir/rilpivirine injectable treatment. Shared manufacturing, injection training, provider relationships, and patient-support infrastructure can reduce incremental commercialization costs.

When does Apretude lose regulatory exclusivity?

Apretude received five years of new chemical entity exclusivity in the United States. Because FDA approved the product on December 20, 2021, the NCE exclusivity period is expected to run through December 20, 2026, subject to FDA regulatory treatment and any applicable patent or pediatric-exclusivity adjustments.[5]

NCE exclusivity blocks FDA approval of an ANDA or 505(b)(2) application that relies on Apretude’s active ingredient during the exclusivity period. It does not prevent competing products from reaching the market through a full NDA pathway.

Apretude does not have biologic exclusivity because cabotegravir is a small-molecule drug, not a biologic. Biosimilar rules therefore do not apply.

FDA regulatory milestones

Date	Event
December 2021	FDA approved Apretude for HIV PrEP
December 2021	FDA approved the oral cabotegravir lead-in option and injection regimen
2022 onward	Commercial rollout and payer adoption
December 2026	Expected end of five-year NCE exclusivity

The product also benefits from patent protection that may extend beyond regulatory exclusivity. The commercial entry date for an ANDA product will depend on the applicable patents, litigation outcomes, settlement terms, and any pediatric or patent-term adjustments.

What patents protect Apretude?

Apretude is protected by a layered intellectual-property estate covering cabotegravir, pharmaceutical compositions, long-acting injectable formulations, manufacturing processes, and methods of preventing HIV infection.

The most commercially important protection is likely the long-acting injectable formulation and its use in HIV prevention. A generic tablet containing cabotegravir would not necessarily substitute for Apretude because Apretude’s clinical and commercial differentiation depends on its injectable depot formulation and dosing schedule.

Patent categories

Patent category	Commercial relevance
Cabotegravir composition patents	Protect the active pharmaceutical ingredient
Injectable formulation patents	Protect the nanosuspension, particle characteristics, excipients, and depot behavior
Method-of-use patents	Protect cabotegravir for HIV PrEP and prevention
Dosing-regimen patents	Protect initiation and every-two-month administration schedules
Manufacturing patents	Protect particle engineering, suspension preparation, sterilization, filling, and scale-up
Device and presentation patents	May protect injection components, packaging, or administration systems

ViiV Healthcare and affiliated GlaxoSmithKline entities have been associated with cabotegravir patent filings. Patent rights differ by jurisdiction, and the effective term depends on filing dates, patent-term adjustment, patent-term extension, terminal disclaimers, and claim scope.

A precise Apretude expiry analysis requires reviewing the current FDA Orange Book listing and relevant patent-family records. The core compound protection is expected to expire before or around the end of the decade, while later-filed formulation, regimen, and manufacturing patents may extend selected protection into the early 2030s. The later patents are more vulnerable to validity and non-infringement challenges because they generally cover narrower technical features than the original compound claims.

What is the Orange Book status of Apretude?

Apretude is an FDA-approved small-molecule prescription drug and is eligible for Orange Book patent listing. The relevant listings may include patents covering the drug substance, drug product, and approved methods of use.

Orange Book-listed patents are important because an ANDA applicant must certify against them. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed. A Paragraph IV notice can trigger patent litigation and a 30-month stay of final FDA approval, subject to statutory conditions.[6]

The commercial importance of each listed patent depends on whether it covers:

1. Cabotegravir itself.
2. The specific injectable formulation.
3. The approved PrEP indication.
4. The dosing schedule.
5. A manufacturing process that a generic applicant must use.

The strongest practical barrier is usually a patent that covers the product’s required formulation or administration characteristics. A weak method-of-use patent may be avoided through labeling strategies, while a formulation patent can be harder to design around.

Which companies are challenging Apretude with generics?

No major Apretude generic launch had been publicly established through June 2024. The absence of a commercial generic does not indicate that the patent estate is unassailable. It reflects the combination of regulatory exclusivity, complex injectable formulation requirements, manufacturing barriers, and the relatively short commercial history of the product.

Potential challengers include large generic manufacturers with sterile injectable and long-acting suspension capabilities. The competitive field is narrower than for oral emtricitabine/tenofovir because an Apretude-equivalent product requires more than active-ingredient synthesis and conventional tablet manufacturing.

Paragraph IV risk

Paragraph IV risk is likely to emerge in stages:

• An ANDA applicant may challenge composition or formulation patents before the end of NCE exclusivity.
• Litigation could delay approval for up to 30 months.
• A challenger could seek a settlement allowing a launch before the latest asserted patent expiry.
• A generic applicant may pursue a non-infringing formulation rather than directly copy every patented feature.
• A 505(b)(2) applicant could develop a related injectable product with different formulation or dosing characteristics.

Publicly disclosed Apretude-specific Paragraph IV litigation and settlement activity was limited through June 2024. That assessment should not be confused with an assurance that no confidential or newly filed challenge exists.

How strong is the Apretude patent estate?

Apretude has a stronger commercial protection profile than a conventional oral small-molecule product because its value depends on formulation, pharmacokinetics, administration, and clinical-use features.

Strengths

• Cabotegravir has a well-established pharmaceutical composition and long-acting delivery platform.
• The injectable product is technically more difficult to replicate than a tablet.
• The approved every-two-month regimen has clinical and operational value.
• Manufacturing scale-up, particle-size control, sterile filling, and suspension stability create barriers beyond patent law.
• A generic applicant may need to demonstrate pharmaceutical equivalence and comparable performance for a complex injectable product.

Weaknesses

• Older composition patents face limited remaining life.
• Narrow formulation claims can be vulnerable to validity attacks.
• Method-of-use claims may be avoided through labeling or physician-use arguments.
• Oral generic PrEP remains a substitute even if it is not therapeutically identical.
• Long-acting cabotegravir’s pharmacokinetic tail creates safety and resistance-management arguments that competitors may use in market positioning.

The patent estate is therefore commercially meaningful but not sufficient by itself to guarantee a long exclusivity period. Manufacturing complexity and provider integration may protect sales after some patents expire, while low-cost oral PrEP limits pricing power before generic injectable entry.

What generic entry risks exist for Apretude?

Apretude faces four distinct entry risks.

Early oral substitution

Patients who value convenience but do not require injections can use generic Truvada-equivalent products. This creates price pressure even without an injectable competitor.

Long-acting formulation competition

A rival long-acting injectable could compete without being an Apretude generic. The rival could use a different integrase inhibitor, delivery platform, or dosing interval.

Public-sector pricing pressure

Government prevention programs can prioritize population coverage and cost per infection averted. Apretude’s clinical efficacy may support reimbursement, but procurement entities may demand discounts, rebates, or outcomes-based contracts.

Patent and regulatory challenges

A Paragraph IV challenge could accelerate the date of generic approval if the challenger prevails or reaches a favorable settlement. The commercial impact would be larger if the entrant receives 180-day first-filer exclusivity and secures substantial payer coverage.

What formulations are protected by Apretude patents?

Apretude’s formulation protection is directed to the long-acting injectable suspension rather than the oral lead-in tablets alone. The commercial formulation uses cabotegravir in a depot-like suspension designed to release active drug over approximately two months.

Relevant technical attributes may include:

• Cabotegravir particle size and morphology.
• Suspension concentration.
• Excipients and surfactants.
• Sterility and injectable viscosity.
• Release profile.
• Storage and reconstitution requirements.
• Manufacturing and filling processes.

A competitor could seek to avoid infringement by modifying one or more of these characteristics. FDA approval would still require a showing of safety, efficacy, quality, and product comparability appropriate to the regulatory pathway.

What litigation and settlement issues affect Apretude?

Through June 2024, Apretude had not generated a publicly prominent patent-litigation record comparable to major small-molecule blockbusters. The principal future litigation issues are likely to involve:

• Whether a rival injectable product practices formulation claims.
• Whether a PrEP indication infringes method-of-use claims.
• Whether ViiV’s patents are enabled and adequately described.
• Whether later-filed patents are obvious over earlier cabotegravir formulations.
• Whether a generic can obtain approval with a restricted label.
• Whether settlement terms create an authorized-generic or licensed-entry pathway.

A settlement could produce a launch date materially earlier than the last patent expiry. ViiV could also use licensing, supply arrangements, or authorized-generic structures to control the transition from branded to generic competition.

How does Apretude compare with Descovy and oral generic PrEP?

Factor	Apretude	Descovy	Generic Truvada-equivalent
Dosing	Injection every two months	Daily tablet	Daily tablet
Adherence profile	Appointment-based	Pill-based	Pill-based
Price position	Premium	Premium	Low cost
Provider involvement	High	Low to moderate	Low to moderate
Key differentiation	Long-acting delivery	Oral tenofovir alafenamide profile	Affordability and availability
Generic pressure	Injectable complexity delays direct copies	Oral generic competition	Already generic
Main market risk	Missed injections and reimbursement	Payer preference and generic substitution	Lower margins

Apretude’s strongest market is patients for whom daily oral adherence is a persistent problem. Its weakest market is price-sensitive patients who can obtain and reliably take generic oral PrEP.

What revenue exposure does Apretude create for ViiV and GSK?

Apretude revenue is not yet large enough to determine GSK’s overall financial performance. ViiV’s HIV business is much larger and remains concentrated in established treatment products.

Its strategic financial importance is higher than its current revenue share for three reasons:

1. It adds a prevention franchise to a treatment-focused portfolio.
2. It extends the commercial use of cabotegravir beyond Cabenuva.
3. It creates a potential long-duration product with recurring administration every two months.

Revenue growth will depend on volume more than price. The product’s premium pricing can support revenue per patient, but payer restrictions and public-health procurement can reduce net price. Administration economics also matter because clinics may require reimbursement for injection services separately from the drug.

What are the likely Apretude launch scenarios after exclusivity?

Scenario	Timing	Market effect
No timely generic	After 2026	ViiV retains premium pricing and expands access
First generic after litigation	Late 2020s	Rapid price erosion among commercial payers
Licensed or authorized generic	Before later patent expiry	Controlled erosion with continued ViiV supply economics
Rival long-acting PrEP product	Before generic entry	Category growth but lower Apretude share
Oral-only substitution	Ongoing	Limits Apretude penetration without directly infringing patents

The most probable commercial pattern is gradual growth before direct injectable competition, followed by sharp net-price pressure once a credible generic or rival long-acting product receives broad payer coverage. The revenue decline could be slower than for a conventional tablet if provider relationships, injection infrastructure, and patient persistence create switching costs.

Key Takeaways

• Apretude is the first FDA-approved long-acting injectable PrEP product and is based on cabotegravir.
• FDA approval occurred in December 2021, with expected five-year NCE exclusivity through December 2026.
• ViiV’s HIV revenue is dominated by treatment products, so Apretude remains a growth asset rather than a primary earnings driver.
• Generic oral PrEP is the product’s largest current competitive constraint.
• Direct injectable competition is harder because of formulation, sterile manufacturing, pharmacokinetic, and administration requirements.
• The patent estate likely includes composition, formulation, dosing, method-of-use, and manufacturing protection, with later-layer protection potentially extending into the early 2030s.
• No major publicly established Apretude generic launch or prominent Paragraph IV litigation had emerged through June 2024.
• Apretude’s commercial performance depends on reimbursement, clinic capacity, injection adherence, and public-health procurement as much as on clinical efficacy.
• A rival long-acting prevention product could pressure Apretude before a conventional generic enters.
• The product’s long-term value comes from its role in ViiV’s broader cabotegravir franchise, including Cabenuva.

FAQs

Is Apretude more effective than Truvada for HIV PrEP?

In the HPTN 083 and HPTN 084 trials, injectable cabotegravir reduced HIV incidence more than daily oral tenofovir-based PrEP in the studied populations. Results reflect both pharmacology and adherence, because missed daily tablets can reduce oral PrEP protection.[1][2]

Can a patient switch from Apretude to generic Truvada?

Yes, but the transition requires clinical management. Because cabotegravir can remain in the body for an extended period after the last injection, clinicians may prescribe oral PrEP during the pharmacokinetic tail and continue HIV testing.

Does Apretude have a biosimilar pathway?

No. Cabotegravir is a small-molecule drug. Potential competitors would generally use an ANDA, 505(b)(2) application, or full NDA pathway rather than the biologics biosimilar pathway.

Will generic Apretude be priced like generic tablets?

Not necessarily. A generic injectable must address sterile manufacturing, formulation equivalence, supply-chain controls, and administration logistics. Those requirements can support higher prices than generic oral PrEP even after patent expiry.

Is Apretude available outside the United States?

Apretude has received approvals or regulatory clearances in multiple jurisdictions, but market availability, product labeling, reimbursement, and patent terms differ by country. ViiV’s international launch strategy is therefore likely to produce uneven uptake across regions.

References

1. Landovitz, R. J., Donnell, D., Clement, M. E., et al. (2021). Cabotegravir for the prevention of HIV-1 in cisgender men who have sex with men. New England Journal of Medicine, 385(7), 595-608.

2. Delany-Moretlwe, S., Hughes, J. P., Bock, P., et al. (2022). Cabotegravir for the prevention of HIV-1 in women: Results from HPTN 084. The Lancet, 399(10337), 1779-1789.

3. U.S. Food and Drug Administration. (2021). Apretude prescribing information. FDA.

4. GSK. (2024). Annual report 2023. GSK plc.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

6. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. FDA.

DrugChatter Q&A for APRETUDE

Apretude launch date?